

GLAXOSMITHKLINE PLC

Form 6-K

January 12, 2015

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending January 2015

GlaxoSmithKline plc
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

Yes No

--

GlaxoSmithKline plc

Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons

In accordance with DTR 3.1.4R(1)(a) GlaxoSmithKline plc ('GSK') was advised on 12 January 2015, of changes in the interests of the following Persons Discharging Managerial Responsibility, following increases in their notional interests in Ordinary Shares, at a price of 1412.75 pence per Share, on the re-investment of dividends paid on Ordinary Shares held in the GlaxoSmithKline Deferred Investment Award Programme.

Director/PDMR	Ordinary Shares
---------------	-----------------

Mr R G Connor	380.408
---------------	---------

Mr S A Hussain	475.510
----------------	---------

Mr D S Redfern	380.408
----------------	---------

Ms C Thomas	380.408
-------------	---------

Dr P J T Vallance	475.510
-------------------	---------

Ms E Walmsley	871.719
---------------	---------

Mrs V A Whyte	106.481
---------------	---------

V A Whyte
Company Secretary
12 January 2015

SIGNATURES

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)

Date: January 12, 2015

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc